Inflammatory Mammary Carcinoma

Inflammatory mammary carcinoma (IMC) is a highly aggressive, rapidly progressive, and almost invariably fatal form of mammary gland neoplasia that occurs primarily in female dogs and, less commonly, in cats. It is characterized by diffuse, edematous, erythematous, and painful swelling of one or more mammary glands, often with associated skin ulceration and systemic signs of inflammation. The term 'inflammatory' refers to the clinical presentation mimicking mastitis, but histopathologically, the tumor is characterized by dermal lymphatic invasion by neoplastic epithelial cells, leading to lymphatic obstruction and intense edema. In dogs, IMC is considered a distinct clinicopathological entity within the spectrum of mammary carcinomas, often associated with a high histologic grade, high mitotic index, and poor differentiation. In cats, inflammatory mammary carcinoma is rare but similarly aggressive. The disease is hormonally influenced, with sex hormones (estrogen and progesterone) playing a role in tumorigenesis, and it typically occurs in intact or spayed females, with a higher incidence in older animals. The condition is a true oncologic emergency due to its rapid progression and poor prognosis, with median survival times often less than 3 months despite aggressive treatment.

The exact etiology of inflammatory mammary carcinoma is multifactorial, involving genetic, hormonal, and environmental factors. Hormonal influences are paramount: prolonged exposure to ovarian hormones, particularly progesterone and estrogen, is a well-established risk factor for mammary tumor development in dogs. Progesterone stimulates mammary gland proliferation and can promote the growth of hormone-dependent tumors. Estrogen may also contribute to tumor initiation and progression. In dogs, the risk of mammary tumors is significantly reduced by ovariohysterectomy (OHE) before the first estrus, with a risk reduction of 0.5% if spayed before first heat, 8% after first heat, and 26% after second heat, highlighting the role of ovarian hormones. Genetic predisposition is evident in certain breeds, such as English Springer Spaniels, Brittany Spaniels, and Cocker Spaniels, which have a higher incidence of mammary tumors, including inflammatory carcinoma. Specific genetic mutations, such as alterations in p53, HER2/neu, and BRCA1/2, have been implicated in canine mammary tumorigenesis, though not specifically for IMC. Environmental factors, including obesity, diet, and exposure to exogenous hormones (e.g., progestin-based contraceptives), may also contribute. Inflammatory mammary carcinoma is not caused by infectious agents; however, secondary bacterial infection of ulcerated lesions can occur, complicating the clinical picture. The molecular mechanisms involve overexpression of growth factors, such as epidermal growth factor receptor (EGFR) and vascular endothelial growth factor (VEGF), leading to increased angiogenesis and lymphatic invasion, which are hallmarks of the inflammatory phenotype.

Inflammatory mammary carcinoma is a rare but devastating disease, accounting for approximately 2-5% of all canine mammary tumors. It occurs predominantly in female dogs, with a median age of onset around 8-10 years, though it can occur in younger animals. Certain breeds are overrepresented, including the English Springer Spaniel, Brittany Spaniel, Cocker Spaniel, and other spaniel breeds, as well as mixed-breed dogs. There is no strong sex predilection beyond the female sex, as males rarely develop mammary tumors. In cats, inflammatory mammary carcinoma is extremely rare, with a few case reports, and it tends to occur in older queens (median age 10-12 years). The disease is more common in intact females, but it can also occur in spayed females, especially if spayed later in life. Parity and number of litters do not appear to be protective, contrary to some other mammary tumors. The incidence is higher in dogs living in regions with less routine spaying, reflecting the hormonal influence. The prognosis is uniformly poor, with a median survival time of 25-60 days in dogs despite treatment, and most animals are euthanized within weeks to months due to progressive disease and poor quality of life.

The pathophysiology of inflammatory mammary carcinoma involves a cascade of events leading to aggressive local invasion and systemic dissemination. The tumor arises from the mammary epithelium, likely from malignant transformation of ductal or alveolar cells. Hormonal stimulation, particularly by progesterone, promotes cell proliferation and may induce mutations. The neoplastic cells acquire invasive properties, infiltrating the dermal lymphatics, which is a hallmark of inflammatory carcinoma. This lymphatic invasion causes obstruction of lymphatic drainage, leading to severe edema, erythema, and pain in the affected mammary glands. The tumor cells also express high levels of pro-angiogenic factors, such as VEGF, leading to increased vascularity and hemorrhage. The intense inflammatory response, characterized by infiltration of neutrophils, macrophages, and lymphocytes, is likely a reaction to tumor necrosis and tissue damage, but it also contributes to the clinical signs. The tumor is highly aggressive, with rapid growth and early metastasis to regional lymph nodes (axillary, inguinal) and distant sites, including lungs, liver, and bones. The systemic effects are mediated by paraneoplastic syndromes, such as hypercalcemia, and by the release of cytokines, leading to fever, lethargy, and cachexia. The molecular pathways involved include activation of the PI3K/AKT/mTOR pathway, overexpression of HER2, and dysregulation of apoptosis. The disease is often hormone receptor-negative, making hormonal therapy ineffective, and it is typically resistant to conventional chemotherapy, contributing to the poor prognosis.

Predisposing factors for inflammatory mammary carcinoma include intrinsic and extrinsic elements. Intrinsic factors: (1) Age: older dogs (median 8-10 years) are at higher risk. (2) Breed: certain breeds, particularly spaniels, have a genetic predisposition. (3) Sex: females are almost exclusively affected; males are extremely rare. (4) Reproductive status: intact females are at higher risk; early OHE (before first estrus) is protective, but late spaying does not eliminate risk. (5) Hormonal imbalances: prolonged exposure to progesterone, either endogenous (during diestrus) or exogenous (e.g., progestin therapy for estrus suppression), increases risk. (6) Genetic mutations: alterations in tumor suppressor genes (p53, BRCA1/2) and oncogenes (HER2) may predispose. Extrinsic factors: (1) Exogenous hormone administration: use of progestins (e.g., medroxyprogesterone acetate) for contraception or treatment of behavioral issues. (2) Obesity: adipose tissue produces estrogen, increasing hormonal stimulation. (3) Diet: high-fat diets may increase risk. (4) Environmental carcinogens: exposure to certain chemicals may contribute. (5) Immunosuppression: chronic immunosuppression may impair tumor surveillance. (6) Prior mammary tumors: history of benign or malignant mammary tumors increases risk of developing new primary tumors, including IMC.

Clinical signs of inflammatory mammary carcinoma are dramatic and rapidly progressive. The hallmark is diffuse, firm, warm, erythematous, and edematous swelling of one or more mammary glands, often involving the entire mammary chain. The skin over the affected glands may be thickened, pitted, and have an orange-peel appearance (peau d'orange). Ulceration and necrosis of the skin are common, leading to serosanguinous or purulent discharge. The affected glands are painful on palpation, and the animal may exhibit signs of systemic illness, including fever, lethargy, anorexia, and weight loss. In advanced cases, there may be lameness due to pain or metastasis to bones. Respiratory signs, such as cough or dyspnea, may indicate pulmonary metastasis. Palpable regional lymphadenopathy (axillary or inguinal) is often present. The disease can be bilateral and may involve all mammary glands. In cats, the clinical presentation is similar but may be more nodular. The rapid onset (days to weeks) is a key feature, distinguishing it from other mammary tumors. The condition can be mistaken for mastitis, but the lack of response to antibiotics and the presence of a mass-like consistency should raise suspicion for neoplasia.

Differential diagnoses for inflammatory mammary carcinoma include: (1) Mastitis: bacterial infection of the mammary gland, often associated with lactation or pseudopregnancy. Key distinguishing features: mastitis typically occurs in lactating or pseudopregnant animals, responds to antibiotics, and may have systemic signs but lacks the rapid progression and lymphatic invasion. Cytology shows septic suppurative inflammation, and culture yields bacteria. (2) Galactostasis: milk stasis, usually in lactating animals, with engorgement but not erythema or pain as severe. (3) Mammary hyperplasia: benign proliferation, often hormone-induced, may be diffuse but lacks the inflammatory component and systemic signs. (4) Mammary adenoma or carcinoma (non-inflammatory): these are usually discrete masses, not diffuse, and lack the severe edema and erythema. (5) Trauma: hematoma or seroma, history of injury, and resolution with time. (6) Abscess: localized, fluctuant, with purulent discharge, responds to drainage and antibiotics. (7) Foreign body reaction: history of penetrating injury. (8) Lymphangitis: inflammation of lymphatic vessels, may be secondary to infection, but lacks the neoplastic component. (9) Systemic edema: due to cardiac or renal disease, but typically not localized to mammary glands. (10) Metastatic disease: other tumors metastasizing to the skin, but rare. Definitive diagnosis requires cytology or biopsy, which will show malignant epithelial cells in the dermal lymphatics.

The diagnostic algorithm for inflammatory mammary carcinoma should be systematic and rapid due to the aggressive nature. Step 1: Clinical triage - assess for systemic signs, pain, and respiratory distress. Step 2: Complete physical examination, including palpation of all mammary glands, regional lymph nodes, and abdominal palpation. Step 3: Fine-needle aspiration (FNA) of the affected mammary gland and any enlarged lymph nodes for cytology. Cytology may show malignant epithelial cells, often with marked anisocytosis and anisokaryosis, and may demonstrate lymphatic invasion if the aspirate includes dermal tissue. Step 4: If cytology is inconclusive, perform a wedge biopsy of the affected skin and mammary tissue for histopathology, which is the gold standard. Step 5: Complete blood count (CBC) and serum biochemistry to assess systemic health and detect paraneoplastic syndromes (e.g., hypercalcemia). Step 6: Thoracic radiographs (three views) to evaluate for pulmonary metastasis. Step 7: Abdominal ultrasonography to assess for liver, spleen, and abdominal lymph node metastasis, and to evaluate the reproductive tract if intact. Step 8: Advanced imaging (CT or MRI) may be considered for surgical planning or to detect occult metastasis, but is not always necessary. Step 9: Hormonal receptor analysis (estrogen and progesterone receptors) on biopsy samples may guide therapy, though IMC is often receptor-negative. Step 10: Staging based on TNM system (Tumor, Node, Metastasis) to determine prognosis. The diagnosis is confirmed by histopathology showing dermal lymphatic invasion by neoplastic cells.

Laboratory findings in inflammatory mammary carcinoma are non-specific but may reflect systemic inflammation and paraneoplastic syndromes. Hematology: leukocytosis with a left shift (increased neutrophils and band cells) is common due to inflammation; toxic neutrophils may be seen. Anemia may be present due to chronic disease or hemorrhage. Thrombocytopenia may occur with disseminated intravascular coagulation (DIC) in advanced cases. Serum biochemistry: hypercalcemia may be present (paraneoplastic hypercalcemia of malignancy), with total calcium > 12 mg/dL; this is due to parathyroid hormone-related protein (PTHrP) secretion. Liver enzymes (ALT, ALP) may be elevated due to metastasis or hepatic stress. Azotemia (elevated BUN and creatinine) may occur with dehydration or renal metastasis. Hypoalbuminemia may be present due to chronic inflammation or protein-losing enteropathy. Urinalysis: may show proteinuria or hematuria if there is urinary tract involvement. Vaginal cytology: not directly relevant, but if the animal is intact, it may show stages of the estrous cycle; however, IMC is not associated with a specific cycle stage. Mammary gland cytology (FNA): shows malignant epithelial cells, often in clusters, with high nuclear-to-cytoplasmic ratio, prominent nucleoli, and mitotic figures. Inflammatory cells (neutrophils, macrophages) may be present. Hormonal assays: serum progesterone and estrogen levels are not typically measured for diagnosis but may be useful if considering hormonal therapy; however, IMC is often hormone receptor-negative. Culture of any discharge may reveal secondary bacterial infection, but this is not diagnostic for IMC.

Imaging plays a crucial role in staging and assessing metastasis. Thoracic radiographs (three views: right lateral, left lateral, and ventrodorsal) are essential to detect pulmonary metastasis, which appears as nodular interstitial or alveolar patterns. In IMC, metastasis is often present at diagnosis, so radiographs may show multiple nodules. Abdominal ultrasonography is used to evaluate the liver, spleen, kidneys, and abdominal lymph nodes for metastasis. The mammary glands themselves can be imaged with ultrasound, which may show diffuse thickening, edema, and increased vascularity, but this is not specific. Mammary masses may be visible as hypoechoic or mixed echogenic areas. Ultrasonography can also guide FNA or biopsy. Computed tomography (CT) provides more detailed evaluation of the mammary glands, regional lymph nodes, and thoracic and abdominal cavities, and is superior for detecting small pulmonary nodules and lymph node involvement. Magnetic resonance imaging (MRI) is rarely used but can delineate soft tissue extension. Lymphoscintigraphy or sentinel lymph node mapping may be used to identify the draining lymph node for biopsy. In cats, thoracic radiographs and abdominal ultrasound are similarly used. Imaging findings are not pathognomonic for IMC but are critical for staging and prognosis.

Cytology: Fine-needle aspiration of the affected mammary gland typically yields highly cellular smears with malignant epithelial cells. These cells are often large, pleomorphic, with high nuclear-to-cytoplasmic ratio, coarse chromatin, prominent nucleoli, and frequent mitotic figures. They may be arranged in clusters or acinar structures. Inflammatory cells, including neutrophils, lymphocytes, and macrophages, are often admixed. The presence of neoplastic cells within lymphatic spaces may be seen if the aspirate includes dermal tissue, but this is not always captured. Cytology of regional lymph nodes may reveal metastatic cells. Histopathology: The gold standard for diagnosis. A wedge biopsy of the affected skin and mammary tissue is preferred over needle biopsy to assess lymphatic invasion. Histologic features include: (1) Dermal lymphatic invasion by cords or nests of malignant epithelial cells, which is the defining feature. (2) Diffuse infiltration of the dermis and subcutaneous tissue by neoplastic cells, often with a desmoplastic reaction. (3) Marked edema and congestion of the dermis. (4) Inflammatory infiltrate, predominantly neutrophils and lymphocytes, surrounding the tumor. (5) High histologic grade, with marked nuclear atypia, high mitotic index (often > 3 mitoses per high-power field), and necrosis. (6) The tumor may be classified as a solid carcinoma, anaplastic carcinoma, or micropapillary carcinoma. Immunohistochemistry can be performed to assess hormone receptor status (estrogen receptor, progesterone receptor), HER2 expression, and proliferation markers (Ki-67). IMC is often triple-negative (ER-, PR-, HER2-), which correlates with poor prognosis. Special stains, such as lymphatic endothelial markers (D2-40), can confirm lymphatic invasion.

Treatment of inflammatory mammary carcinoma is challenging and often palliative due to the aggressive nature. The primary goals are to control local disease, manage systemic signs, and improve quality of life. Surgical resection (mastectomy) is generally not recommended as the sole treatment because the diffuse nature of the disease makes complete excision difficult, and surgery may exacerbate inflammation and wound healing issues. However, in some cases, a radical mastectomy (removal of the entire mammary chain) may be attempted if the disease is localized, but recurrence is high. Medical management includes: (1) Nonsteroidal anti-inflammatory drugs (NSAIDs) to reduce inflammation and pain, e.g., carprofen (2.2 mg/kg PO q12h) or meloxicam (0.1 mg/kg PO q24h). (2) Corticosteroids (e.g., prednisone 0.5-1 mg/kg PO q24h) may be used for their anti-inflammatory and anti-edema effects, but they may have immunosuppressive effects. (3) Chemotherapy: Various protocols have been tried, but response rates are low. Doxorubicin (30 mg/m² IV q3 weeks) is commonly used, often in combination with cyclophosphamide (50-100 mg/m² PO q3 weeks) or vincristine. However, IMC is often chemoresistant. Metronomic chemotherapy with low-dose cyclophosphamide (10 mg/m² PO q24h) and piroxicam (0.3 mg/kg PO q24h) has been used to target tumor angiogenesis. (4) Tyrosine kinase inhibitors, such as toceranib (Palladia, 2.75 mg/kg PO q48h), may be considered, though evidence is limited. (5) Radiation therapy may provide palliative relief for pain and edema, but it is not curative. (6) Supportive care: fluid therapy, nutritional support, and wound care for ulcerated lesions. Antibiotics are indicated if secondary bacterial infection is present. Hormonal therapy (e.g., anti-estrogens like tamoxifen) is generally ineffective due to receptor negativity. Given the poor prognosis, euthanasia is often elected when quality of life deteriorates. In cats, similar approaches are used, but chemotherapy options are more limited.

The prognosis for inflammatory mammary carcinoma is grave. Median survival time in dogs is reported to be 25-60 days from diagnosis, even with treatment. Most dogs are euthanized within weeks to months due to progressive disease, pain, and poor quality of life. Factors associated with a worse prognosis include: presence of metastasis at diagnosis, high histologic grade, triple-negative receptor status, and lack of response to chemotherapy. Cats have a similarly poor prognosis, with median survival times of less than 6 months. The disease is almost always fatal, and long-term survival is extremely rare. Palliative care can improve quality of life temporarily, but the disease is ultimately incurable. Owners should be counseled about the poor prognosis and the option of humane euthanasia when the animal's suffering becomes unacceptable.

Follow-up for inflammatory mammary carcinoma is focused on monitoring disease progression and managing complications. Due to the rapid course, follow-up visits are frequent, often weekly or biweekly. At each visit, a physical examination should assess the size and appearance of the mammary lesions, pain, and any new masses. Thoracic radiographs should be repeated monthly to monitor for pulmonary metastasis. Abdominal ultrasound may be repeated if abdominal metastasis is suspected. Blood work (CBC, biochemistry) should be checked regularly to monitor for paraneoplastic syndromes (e.g., hypercalcemia) and treatment-related toxicity. If the animal is on chemotherapy, blood counts should be monitored before each dose. Pain assessment and management should be adjusted as needed. Quality of life assessments should be performed, and the owner should be educated on signs of deterioration, such as difficulty breathing, severe pain, or inappetence, which may indicate the need for euthanasia. If the animal is intact, ovariohysterectomy may be recommended to remove hormonal stimulation, but this does not improve the prognosis for IMC. Breeding is absolutely contraindicated due to the genetic and hormonal risks.

Clinical Pearls: (1) Inflammatory mammary carcinoma is a clinical diagnosis based on the rapid onset of diffuse, erythematous, edematous mammary gland swelling; do not delay biopsy. (2) Always perform thoracic radiographs at diagnosis because metastasis is common. (3) Histopathology is essential to confirm dermal lymphatic invasion; a wedge biopsy is preferred over FNA. (4) IMC is often triple-negative, so hormonal therapy is ineffective; focus on palliative care. (5) NSAIDs and corticosteroids can provide significant relief from inflammation and pain. (6) Consider metronomic chemotherapy as a less toxic option for palliative care. (7) Euthanasia is a humane option when quality of life is poor. Pitfalls: (1) Mistaking IMC for mastitis and treating with antibiotics without biopsy, delaying diagnosis. (2) Attempting surgical excision as a curative treatment, which is often futile and may worsen the condition. (3) Underestimating the aggressiveness of the disease and providing false hope to owners. (4) Failing to monitor for hypercalcemia, which can cause renal failure. (5) Using high-dose chemotherapy that may cause severe toxicity without benefit. (6) Ignoring the need for pain management. (7) Not discussing the poor prognosis and end-of-life options early.

Current drug protocols for inflammatory mammary carcinoma focus on palliative care and attempted tumor control. (1) NSAIDs: Carprofen (Rimadyl) 2.2 mg/kg PO q12h; Meloxicam (Metacam) 0.1 mg/kg PO q24h; Firocoxib (Previcox) 5 mg/kg PO q24h. (2) Corticosteroids: Prednisone 0.5-1 mg/kg PO q24h, tapering to lowest effective dose. (3) Chemotherapy: Doxorubicin (Adriamycin) 30 mg/m² IV q3 weeks, with cardiac monitoring; Cyclophosphamide (Cytoxan) 50-100 mg/m² PO q3 weeks, or metronomic dosing at 10 mg/m² PO q24h; Vincristine 0.5-0.7 mg/m² IV q3 weeks; Carboplatin 300 mg/m² IV q3 weeks (less commonly used). (4) Tyrosine kinase inhibitor: Toceranib (Palladia) 2.75 mg/kg PO q48h, with monitoring for gastrointestinal and hematologic toxicity. (5) Bisphosphonates: For hypercalcemia, pamidronate 1.3-2 mg/kg IV diluted in saline over 2 hours, or alendronate 10 mg/dog PO q24h. (6) Supportive care: Fluid therapy with 0.9% NaCl for hypercalcemia; antiemetics (maropitant 1 mg/kg SC q24h) if chemotherapy-induced nausea; appetite stimulants (mirtazapine 3.75 mg/dog PO q24h). (7) Antibiotics: If secondary infection, amoxicillin-clavulanate 13.75 mg/kg PO q12h. (8) Analgesics: Tramadol 2-5 mg/kg PO q8-12h; gabapentin 5-10 mg/kg PO q8-12h for neuropathic pain. All protocols should be adjusted based on patient tolerance and response.

Evidence-based literature on inflammatory mammary carcinoma is limited due to its rarity, but several studies provide insights. A retrospective study by Peña et al. (2013) evaluated 50 dogs with IMC and found a median survival of 30 days, with no significant difference between treatment groups (surgery, chemotherapy, or palliative care). Another study by Sorenmo et al. (2011) reported that IMC is associated with a high incidence of metastasis at diagnosis and poor response to doxorubicin-based chemotherapy. A study by Tran et al. (2016) investigated the role of toceranib in canine mammary tumors, including IMC, and found modest response rates. In cats, a case series by Gimenez et al. (2010) described three cases of feline IMC, all with rapid progression and death within 2 months. Consensus guidelines from the World Small Animal Veterinary Association (WSAVA) and the American College of Veterinary Internal Medicine (ACVIM) recommend that IMC be treated as a systemic disease, with palliative intent, and that surgery be avoided. The use of metronomic chemotherapy has been supported by some studies, showing improved quality of life and prolonged survival in some cases, but evidence is anecdotal. Overall, the literature underscores the poor prognosis and the need for early recognition and humane management.